Stock ANNX ANNEXIN PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Company Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 08:59:49 03/05/2024 pm IST 		5-day change 1st Jan Change
0.312 SEK +1.30% Intraday chart for Annexin Pharmaceuticals AB +5.05% +20.00%
30/04 Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals CI
25/04 Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study CI

Business Summary

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Company’s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Number of employees: 4

Managers

Managers TitleAgeSince
Anna Frostegård FOU
 Founder 51 01/14/01
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 01/18/01
Susanne Andersson DFI
 Director of Finance/CFO 53 11/23/11
Susan Suchdev COO
 Chief Operating Officer 52 -
Alain Thibault PRN
 Corporate Officer/Principal - 18/23/18

Members of the board

Members of the board TitleAgeSince
Uli Alf Hacksell CHM
 Chairman 74 01/21/01
Mårten Österlund BRD
 Director/Board Member 67 01/21/01
Nils Anders Haegerstrand CEO
 Chief Executive Officer 63 01/18/01
Carl-Fredrik Lindner BRD
 Director/Board Member 48 01/17/01
Erik Johan Frostegård BRD
 Director/Board Member 65 01/16/01
Gisela Marie Sitbon BRD
 Director/Board Member 66 01/17/01
Curt Mikael von Euler-Chelpin BRD
 Director/Board Member 71 -
Anthon Jahreskog BRD
 Director/Board Member 44 01/22/01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 346,583,688 75,900,956 ( 21.90 %) 0 21.90 %

Company contact information

Annexin Pharmaceuticals AB

Kammakargatan 48

111 60, Stockholm

+

http://www.annexinpharma.com
address Annexin Pharmaceuticals AB(ANNX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
ANNEXIN PHARMACEUTICALS AB Stock Annexin Pharmaceuticals AB
+20.00% 10.01M
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ANNX Stock
  4. Company Annexin Pharmaceuticals AB